Details der Publikation - Status Report on COVID-19 Vaccines Development

Status Report on COVID-19 Vaccines Development

Purpose of Review The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has affected lives of billions of individuals, globally. There is an urgent need to develop interventions including vaccines to control the ongoing pandemic. Recent Findings Development of tools for fast-tracked testing including small and large animal models for vaccine efficacy analysis, assays for immunogenicity assessment, critical reagents, international biological standards, and data sharing allowed accelerated development of vaccines. More than 300 vaccines are under development and 9 of them are approved for emergency use in various countries, with impressive efficacy ranging from 50 to 95%. Recently, several new SARS-CoV-2 variants have emerged and are circulating globally, and preliminary findings imply that some of them may escape immune responses against previous variants and diminish efficacy of current vaccines. Most of these variants acquired new mutations in their surface protein (Spike) which is the antigen in most of the approved/under development vaccines. Summary In this review, we summarize novel and traditional approaches for COVID-19 vaccine development including inactivated, attenuated, nucleic acid, vector and protein based. Critical assessment of humoral and cell-mediated immune responses induced by vaccines has shown comparative immunogenicity profiles of various vaccines in clinical phases. Recent reports confirmed that some currently available vaccines provide partial to complete protection against emerging SARS-CoV-2 variants. If more mutated variants emerge, current vaccines might need to be updated accordingly either by developing vaccines matching the circulating strain or designing multivalent vaccines to extend the breadth..

Medienart:	E-Artikel

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	Zur Gesamtaufnahme - volume:23
Enthalten in:	Current infectious disease reports - 23(2021), 6 vom: 14. Apr.

Sprache:	Englisch

Beteiligte Personen:	Kumar, Arun [VerfasserIn] Dowling, William E. [VerfasserIn] Román, Raúl Gómez [VerfasserIn] Chaudhari, Amol [VerfasserIn] Gurry, Celine [VerfasserIn] Le, Tung Thanh [VerfasserIn] Tollefson, Stig [VerfasserIn] Clark, Carolyn E [VerfasserIn] Bernasconi, Valentina [VerfasserIn] Kristiansen, Paul A [VerfasserIn]

Links:	Volltext [kostenfrei]

BKL:	44.75$jInfektionskrankheiten$jparasitäre Krankheiten$XMedizin
Themen:	Animal models Assays and standards COVID-19 vaccines Preclinical and clinical development SARS-CoV-2 SARS-CoV-2 variants

Anmerkungen:	© The Author(s) 2021

doi:	10.1007/s11908-021-00752-3

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2124918354

Internformat


LEADER	01000naa a22002652 4500
001	OLC2124918354
003	DE-627
005	20230505100822.0
007	cr uuu---uuuuu
008	230505s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s11908-021-00752-3 \|2 doi
035			\|a (DE-627)OLC2124918354
035			\|a (DE-He213)s11908-021-00752-3-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a 44.75$jInfektionskrankheiten$jparasitäre Krankheiten$XMedizin \|2 bkl
100	1		\|a Kumar, Arun \|e verfasserin \|0 (orcid)0000-0003-4483-7585 \|4 aut
245	1	0	\|a Status Report on COVID-19 Vaccines Development
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s) 2021
520			\|a Purpose of Review The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has affected lives of billions of individuals, globally. There is an urgent need to develop interventions including vaccines to control the ongoing pandemic. Recent Findings Development of tools for fast-tracked testing including small and large animal models for vaccine efficacy analysis, assays for immunogenicity assessment, critical reagents, international biological standards, and data sharing allowed accelerated development of vaccines. More than 300 vaccines are under development and 9 of them are approved for emergency use in various countries, with impressive efficacy ranging from 50 to 95%. Recently, several new SARS-CoV-2 variants have emerged and are circulating globally, and preliminary findings imply that some of them may escape immune responses against previous variants and diminish efficacy of current vaccines. Most of these variants acquired new mutations in their surface protein (Spike) which is the antigen in most of the approved/under development vaccines. Summary In this review, we summarize novel and traditional approaches for COVID-19 vaccine development including inactivated, attenuated, nucleic acid, vector and protein based. Critical assessment of humoral and cell-mediated immune responses induced by vaccines has shown comparative immunogenicity profiles of various vaccines in clinical phases. Recent reports confirmed that some currently available vaccines provide partial to complete protection against emerging SARS-CoV-2 variants. If more mutated variants emerge, current vaccines might need to be updated accordingly either by developing vaccines matching the circulating strain or designing multivalent vaccines to extend the breadth.
650		4	\|a SARS-CoV-2
650		4	\|a COVID-19 vaccines
650		4	\|a Animal models
650		4	\|a Preclinical and clinical development
650		4	\|a Assays and standards
650		4	\|a SARS-CoV-2 variants
700	1		\|a Dowling, William E. \|4 aut
700	1		\|a Román, Raúl Gómez \|4 aut
700	1		\|a Chaudhari, Amol \|4 aut
700	1		\|a Gurry, Celine \|4 aut
700	1		\|a Le, Tung Thanh \|4 aut
700	1		\|a Tollefson, Stig \|4 aut
700	1		\|a Clark, Carolyn E \|4 aut
700	1		\|a Bernasconi, Valentina \|4 aut
700	1		\|a Kristiansen, Paul A \|4 aut
773	0	8	\|i Enthalten in \|t Current infectious disease reports \|d Springer US, 1999 \|g 23(2021), 6 vom: 14. Apr. \|h Online-Ressource \|w (DE-627)357168305 \|w (DE-600)2094167-5 \|w (DE-576)306830655 \|x 1534-3146 \|7 nnns
773	1	8	\|g volume:23 \|g year:2021 \|g number:6 \|g day:14 \|g month:04
856	4	0	\|u https://dx.doi.org/10.1007/s11908-021-00752-3 \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2136
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 44.75$jInfektionskrankheiten$jparasitäre Krankheiten$XMedizin \|q VZ \|0 106415948 \|0 (DE-625)106415948
951			\|a AR
952			\|d 23 \|j 2021 \|e 6 \|b 14 \|c 04

Status Report on COVID-19 Vaccines Development

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände